Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom

ObjectiveTo report the identification and results of susceptibility testing for fungal isolates from the cornea or contact lens care systems.Materials and methodsIn this retrospective epidemiological study, we searched the results of fungal cultures from cornea or contact lens systems referred for identification and susceptibility testing to the United Kingdom National Mycology Reference Laboratory between October 2016 and March 2022. For each fungal isolate, we recorded the genus and species of the fungus and the minimum inhibitory concentration (MIC) to six antifungal agents available to treat corneal infection (amphotericin, econazole, itraconazole, natamycin, posaconazole, and voriconazole).ResultsThere were 600 isolates from 585 patients, comprising 374 (62%) from corneal samples and 226 from contact lenses and care systems, of which 414 (69%) isolates were moulds (filamentous fungi) and 186 (31%) were yeasts. The most frequent moulds isolated were Fusarium spp (234 isolates, 39%) and Aspergillus spp (62, 10%). The most frequent yeasts isolated were Candida spp (112, 19%), predominantly Candida parapsilosis (65, 11%) and Candida albicans (33, 6%), with 35 isolates (6%) of Meyerozyma guilliermondii. In vitro susceptibility was greatest for natamycin (347 moulds tested, mode 4 mg/L, range 0.25-64 mg/L; 98 yeasts tested, mode 4 mg/L, range 0.5-32 mg/L), with susceptibility for 94% for moulds and 99% yeasts. Of the 16 isolates interpreted as highly resistant to natamycin (MIC & GE;16 mg/L), 13 were Aspergillus flavus complex.ConclusionsIn vitro susceptibility supports the use of natamycin for the empiric treatment of fungal keratitis in the UK.

Automated summary

This study reports the identification and susceptibility testing results of fungal isolates from the cornea or contact lens care systems. The results show that natamycin has good in vitro susceptibility for the treatment of fungal keratitis in the UK.